Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Saliva proteins may reveal hidden clues about gum disease

NCT ID NCT07601685

Knowledge-focused Sponsor: Inonu University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at proteins that help parts of cells communicate—specifically mitochondria and the endoplasmic reticulum—in people with healthy gums, gingivitis, or advanced gum disease. Researchers measure these proteins in saliva and gum fluid to see if they relate to inflammation and tissue damage. The goal is to better understand the biological processes behind gum disease, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain proteins are linked to gum disease severity, this could point toward new diagnostic markers or treatment targets.
What could go wrong
This is a small observational study (48 people) that only measures proteins—it does not test any treatment. Results may not apply to smokers or people with other health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

48 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Systemically healthy, non-smoking individuals aged 18-65 years who presented to the Department of Periodontology, Faculty of Dentistry, Inonu University, Malatya, Turkiye for examination and/or treatment between January 2024 and May 2024. Participants were classified into three groups based on the 2017 World Workshop criteria: periodontally healthy (n=16), gingivitis (n=16), and Stage III Grade B periodontitis (n=16), with equal sex distribution (8 males and 8 females per group).

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Systemically healthy individuals aged 18-65 years * Non-smokers or smoking cessation more than 5 years ago * Healthy group: No history of periodontal disease, ≥20 teeth, probing depth (PD) ≤3 mm at all sites, bleeding on probing (BOP) \<10%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Gingivitis group: No history of periodontal disease, ≥20 teeth, PD ≤3 mm at all sites, BOP ≥30%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Periodontitis group: ≥15 teeth, \>30% of teeth affected by periodontal disease, PD ≥6 mm, clinical attachment loss (CAL) ≥5 mm, vertical bone loss ≥3 mm, Class II or III furcation involvement, radiographic alveolar bone loss extending to the middle third or beyond (≥33%), bone loss-to-age ratio between 0.25 and 1.00 Exclusion Criteria: * Periodontal treatment or antibiotic use within the past 6 months * Fewer than 20 teeth (excluding third molars) * Presence of any systemic disease * Current smoking or cessation within the past 5 years * Use of immunosuppressive medication * Alcohol consumption * Regular medication use * Pregnancy or lactation * Need for antibiotic prophylaxis prior to dental procedures * Prosthetic restorations on the teeth selected for sampling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarker discovery and validation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gingivitis periodontal disorder periodontitis Spinocerebellar Ataxias

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarker discovery and validation Gingivitis and periodontal diseases Pathways Periodontitis

Contacts and locations

Locations

  • Inönü University Faculty of Dentistry, Department of Periodontology

    Malatya, Malatya, 44210, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.